cilexetil
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 21, 2022 (NCT05388448)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- AngiotensinogenANTAGONIST
AGT antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)OC(=O)OC1CCCCC1- Mol. weight
- 186.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107073 ↗
- ChEMBLCHEMBL2104038 ↗
Also known as
- cilexetil
- cilexetil
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05388448 | Phase 2 | Apr 21, 2022 | European and Developing Countries Clinical Trials Partnership (EDCTP), GlaxoSmithKline, TASK Applied Science |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| European and Developing Countries Clinical Trials Partnership (EDCTP) | Academic/Hospital | 1 | 0 | 1 | 2022 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2022 |
| TASK Applied Science | For profit | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1